Phase 2Recruiting
Emapalumab Prevention of CAR-T Cell Associated Toxicities
A Phase 2 Trial of Emapalumab for the Prevention of CAR-T Cell Associated Toxicities
- Sponsor
- Marcela V. Maus, M.D.,Ph.D. (Academic or other)
- Enrolment
- 28 planned
- Conditions
- Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma; Primary Mediastinal Large B-cell Lymphoma; High-grade B-cell Lymphoma; Follicular Lymphoma
- Interventions
- Emapalumab; Cyclophosphamide; Fludarabine Phosphate; Axicabtagene Ciloleucel; Dexamethasone; Lisocabtagene maraleucel
- Ages
- adults, older adults
- Registry
- NCT06550141
Full record on ClinicalTrials.gov
From the registry
This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL). The research study involves the following study interventions: * Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy) * Axicabtagene Ciloleucel or Lisocabtagene Maraleucel * Emapalumab
Primary outcomes
- Incidence of grade 2+ CRS per ASTCT
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered